Luhan Pharmachem Co., Ltd.

Zoledronic acid (INN) or zoledronate (marketed by Novartis under the trade names Zometa, Zomera, Aclasta andReclast) is a bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such asmultiple myeloma and prostate cancer, as well as for treating osteoporosis. It can also be used to treathypercalcemia of malignancy and can be helpful for treating pain from bone metastases.

An annual dose of zoledronic acid may also prevent recurring fractures in patients with a previous hip fracture.

Reclast is a single 5 mg infusion for the treatment of Paget's disease of bone. In 2007, the U.S. Food and Drug Administration (FDA) also approved Reclast for the treatment of postmenopausal osteoporosis.

cas no.:118072-93-8